The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 3, 2011, Pages 799-806

  Burns, Christopher J ^a   Fantino, Emmanuelle ^a   Powell, Andrew K ^a   Shnyder, Steven D ^b   Cooper, Patricia A ^b   Nelson, Stuart ^b   Christophi, Christopher ^c   Malcontenti Wilson, Cathy ^c   Dubljevic, Valentina ^a   Harte, Michael F ^a   Joffe, Max ^a   Phillips, Ian D ^a   Segal, David ^a   Wilks, Andrew F ^a   Smith, Gregg D ^a  

^a YM BioSciences Australia   (Australia)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 3 [2 METHOXY 4 [5 METHYL 4 [[1 (PYRIDIN 3 YL)BUTYL]AMINO]PYRIMIDIN 2 YL]PHENYL]UREA; ANGIOGENESIS INHIBITOR; CYT 997; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CORROSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; PYRIMIDINES; TIME FACTORS; TUBULIN MODULATORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81555204261     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.186965     Document Type: Article

References (38)

1. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, and Price PM (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:2823-2830. (Pubitemid 46621829)
2. Bonezzi K, Taraboletti G, Borsotti P, Bellina F, Rossi R, and Giavazzi R (2009) Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles. J Med Chem 52:7906-7910.
3. Burns CJ, Fantino E, Phillips ID, Su S, Harte MF, Bukczynska PE, Frazzetto M, Joffe M, Kruszelnicki I, Wang B, et al. (2009a) CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Mol Cancer Ther 8:3036-3045.
4. Burns CJ, Harte MF, Bu X, Fantino E, Joffe M, Sikanyika H, Su S, Tranberg CE, Wilson N, Charman SA, et al. (2009b) Discovery of CYT997: a structurally novel orally active microtubule targeting agent. Bioorg Med Chem Lett 19:4639-4642.
5. Chan LS, Malcontenti-Wilson C, Muralidharan V, and Christophi C (2007) Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis. Anticancer Res 27:2317-2323. (Pubitemid 47228070)
6. Chan LS, Malcontenti-Wilson C, Muralidharan V, and Christophi C (2008) Alterations in vascular architecture and permeability following OXi4503 treatment. Anticancer Drugs 19:17-22. (Pubitemid 350190964)
7. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, and Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834. (Pubitemid 27209705)
8. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. (2002) ZD6126: a novel vasculartargeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253. (Pubitemid 36025246)
9. Farace F, Massard C, Borghi E, Bidart JM, and Soria JC (2007) Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 18:1421-1422. (Pubitemid 47305018)
10. Francesconi A, Kotasek D, Burge M, Smith G, and Lickliter J (2009) Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer. J Clin Oncol 27(Suppl):15s.
11. Hamel E (1996) Antimitotic natural products and their interactions with tubulin. Med Res Rev 16:207-231.
12. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, et al. (2006) The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 12:2834-2840.
13. Hearn BR, Shaw SJ, and Myles DC (2007) Microtubule targeting agents, in Comprehensive Medicinal Chemistry II (Taylor JB and Triggle DJ eds) pp 81-110, Elsevier, Amsterdam, The Netherlands .
14. Honore S, Pasquier E, and Braguer D (2005) Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62:3039-3056. (Pubitemid 43004753)
15. Hori K and Saito S (2004) Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). Br J Cancer 90:549-553. (Pubitemid 38250657)
16. Horsman MR and Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11520-11539. (Pubitemid 46094158)
17. Kanthou C and Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060-2069. (Pubitemid 34525489)
18. Kanthou C and Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90:284-294.
19. Lickliter JD, Francesconi AB, Smith G, Burge M, Coulthard A, Rose S, Griffin M, Milne R, McCarron J, Yeadon T, et al. (2010) Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Br J Cancer 103:597-606.
20. Luo Y, Hradil VP, Frost DJ, Rosenberg SH, Gordon GB, Morgan SJ, Gagne GD, Cox BF, Tahir SK, and Fox GB (2009) ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anticancer Drugs 20:483-492.
21. Malcontenti-Wilson C, Chan L, Nikfarjam M, Muralidharan V, and Christophi C (2008) Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. J Gastroenterol Hepatol 23:e96-e104. (Pubitemid 352019401)
22. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, and O'Brien PE (2001) Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7:1052-1060. (Pubitemid 32708745)
23. Markland FS, Swenson S, Minea R (2010) Tumor Angiogenesis: From Molecular Mechanisms to Targeted Therapy, Wiley-VCH, Hoboken, NJ.
24. Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, and Neuteboom ST (2006) NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 17:25-31.
25. Pasquier E, Carré M, Pourroy B, Camoin L, Rebaï O, Briand C, and Braguer D (2004) Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 3:1301-1310. (Pubitemid 39440174)
26. Pettit GR, Temple C Jr, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, and Bansal N (1995) Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299-309.
27. Reyes-Aldasoro CC, Wilson I, Prise VE, Barber PR, Ameer-Beg M, Vojnovic B, Cunningham VJ, and Tozer GM (2008) Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo. Microcirculation 15:65-79.
28. Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594-2601.
29. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787. (Pubitemid 44454154)
30. Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, et al. (2009) Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 69:7524-7528.
31. Shi W and Siemann DW (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19:1045-1050. (Pubitemid 41631508)
32. Tozer GM, Ameer-Beg SM, Baker J, Barber PR, Hill SA, Hodgkiss RJ, Locke R, Prise VE, Wilson I, and Vojnovic B (2005a) Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev 57:135-152. (Pubitemid 39424069)
33. Tozer GM, Kanthou C, and Baguley BC (2005b) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435. (Pubitemid 40791485)
34. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, and Dammacco F (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143-4155.
35. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, and Giaccone G (1998) Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5:249-255.
36. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, et al. (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006. (Pubitemid 41567565)
37. Yeung SC, She M, Yang H, Pan J, Sun L, and Chaplin D (2007) Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 92:2902-2909. (Pubitemid 47236348)
38. Yin S, Cabral F, and Veeraraghavan S (2007) Amino acid substitutions at proline 220 of β-tubulin confer resistance to paclitaxel and colcemid. Mol Cancer Ther 6:2798-2806. (Pubitemid 350058158)